Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for ITCI
| Stock Name | Intracellular Th |
| Ticker | ITCI(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US46116X1019 |
| LEI | 5299002U2KGF193IJA20 |
Show aggregate ITCI holdings
News associated with ITCI
- Xponance Inc. Grows Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Xponance Inc. grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.6% during the first quarter, HoldingsChannel reports. The firm owned 14,093 shares of the biopharmaceutical company’s stock after acquiring an additional 484 shares during the period. Xponance Inc.’s holdings in Intra-Cellular Therapies were worth $1,859,000 at the end of the most […] - 2025-07-15 06:28:29
- Crossmark Global Holdings Inc. Makes New $211,000 Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Crossmark Global Holdings Inc. acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,603 shares of the biopharmaceutical company’s stock, valued at approximately $211,000. Other hedge funds and other […] - 2025-07-14 06:18:53
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $109.70 Consensus Price Target from Brokerages
- Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been given a consensus recommendation of “Hold” by the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year […] - 2025-07-11 04:00:57
- 5,557 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Concurrent Investment Advisors LLC
- Concurrent Investment Advisors LLC purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,557 shares of the biopharmaceutical company’s stock, valued at approximately $733,000. Several other institutional investors and hedge […] - 2025-07-10 05:53:04
- Teacher Retirement System of Texas Sells 2,427 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Teacher Retirement System of Texas decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 8.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,732 shares of the biopharmaceutical company’s stock after selling 2,427 shares […] - 2025-07-09 05:32:56
- Advisor Resource Council Takes $258,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Advisor Resource Council acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,953 shares of the biopharmaceutical company’s stock, valued at approximately $258,000. Several other institutional investors and […] - 2025-06-24 05:23:02
- Merit Financial Group LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Merit Financial Group LLC grew its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 13.5% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,798 shares of the biopharmaceutical company’s stock after buying an additional 333 shares during the period. Merit Financial […] - 2025-06-12 04:54:49
- 1,900 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by SeaCrest Wealth Management LLC
- SeaCrest Wealth Management LLC bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,900 shares of the biopharmaceutical company’s stock, valued at approximately $251,000. A number of other institutional investors and […] - 2025-06-09 05:55:06
- Wealth Enhancement Advisory Services LLC Has $1 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Wealth Enhancement Advisory Services LLC boosted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,010 shares of the biopharmaceutical company’s stock after purchasing an additional 3,200 shares during the period. Wealth Enhancement […] - 2025-06-09 04:44:53
- Tidal Investments LLC Purchases 215 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Tidal Investments LLC raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 4.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,027 shares of the biopharmaceutical company’s stock after acquiring an additional 215 shares during the […] - 2025-05-30 05:15:06
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Lifted by Cetera Investment Advisers
- Cetera Investment Advisers increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 35.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,459 shares of the biopharmaceutical company’s stock after purchasing an additional 1,175 shares during the quarter. Cetera Investment Advisers’ holdings in Intra-Cellular Therapies were worth $372,000 as […] - 2025-05-30 04:38:52
- ProShare Advisors LLC Reduces Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- ProShare Advisors LLC cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 19.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,020 shares of the biopharmaceutical company’s stock after selling 1,224 shares during the quarter. ProShare Advisors […] - 2025-05-28 05:12:54
- Quantinno Capital Management LP Purchases New Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Quantinno Capital Management LP purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 3,062 shares of the biopharmaceutical company’s stock, valued at approximately $256,000. A number of other institutional investors and hedge funds have also recently added to or reduced their […] - 2025-05-27 04:58:54
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Dimensional Fund Advisors LP
- Dimensional Fund Advisors LP grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.4% in the 4th quarter, HoldingsChannel reports. The firm owned 84,391 shares of the biopharmaceutical company’s stock after acquiring an additional 1,186 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Intra-Cellular Therapies were worth $7,048,000 […] - 2025-05-12 04:47:03
- StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
- Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Other equities analysts have also issued research reports about the stock. Piper Sandler reissued a “neutral” rating […] - 2025-05-09 02:14:56
- MetLife Investment Management LLC Sells 145 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- MetLife Investment Management LLC trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,343 shares of the biopharmaceutical company’s stock after selling 145 shares during the period. MetLife […] - 2025-05-06 05:01:00
- Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com
- StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ITCI. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price […] - 2025-04-30 04:44:58
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Mariner LLC
- Mariner LLC lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 7.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 10,497 shares of the biopharmaceutical company’s stock after purchasing an additional 758 shares during the period. Mariner LLC’s holdings in Intra-Cellular Therapies were worth $877,000 at the end […] - 2025-04-29 05:00:50
- Sterling Capital Management LLC Has $139,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Sterling Capital Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 11.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,663 shares of the biopharmaceutical company’s stock after selling 207 shares during the quarter. Sterling […] - 2025-04-22 05:16:58
- Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com
- StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price […] - 2025-04-22 02:48:50
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Decreased by Russell Investments Group Ltd.
- Russell Investments Group Ltd. reduced its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 39.4% during the fourth quarter, Holdings Channel reports. The firm owned 32,306 shares of the biopharmaceutical company’s stock after selling 21,017 shares during the period. Russell Investments Group Ltd.’s holdings in Intra-Cellular Therapies were worth $2,698,000 at the end […] - 2025-04-18 05:26:53
- Envestnet Asset Management Inc. Sells 2,317 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Envestnet Asset Management Inc. cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,662 shares of the biopharmaceutical company’s stock after selling 2,317 shares during the period. Envestnet Asset […] - 2025-04-18 04:45:00
- Legal & General Group Plc Sells 8,681 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
- Legal & General Group Plc cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,161 shares of the biopharmaceutical company’s stock after selling 8,681 shares during […] - 2025-04-17 06:08:51
- StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
- Equities researchers at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock. ITCI has been the subject of a number of other research reports. Mizuho downgraded shares of Intra-Cellular Therapies from […] - 2025-04-15 02:16:49
- Cantor Fitzgerald Reiterates “Neutral” Rating for Intra-Cellular Therapies (NASDAQ:ITCI)
- Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 0.10% from the company’s […] - 2025-04-04 02:56:51
- Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $106.08
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the […] - 2025-04-02 03:09:06
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Vanguard Group Inc.
- Vanguard Group Inc. increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.0% during the 4th quarter, Holdings Channel reports. The fund owned 9,721,360 shares of the biopharmaceutical company’s stock after purchasing an additional 93,107 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of Intra-Cellular Therapies worth $811,928,000 […] - 2025-03-30 06:28:47
- 19,043 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Proficio Capital Partners LLC
- Proficio Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 4th quarter, Holdings Channel reports. The firm purchased 19,043 shares of the biopharmaceutical company’s stock, valued at approximately $1,590,000. A number of other institutional investors also recently bought and sold shares of ITCI. Wasatch Advisors […] - 2025-03-20 05:50:52
- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Lowered by PNC Financial Services Group Inc.
- PNC Financial Services Group Inc. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 4.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,034 shares of the biopharmaceutical company’s stock after selling 357 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Intra-Cellular Therapies were worth $671,000 […] - 2025-03-19 06:03:17
- SCHA, ITCI, AFRM, EXEL: Large Outflows Detected at ETF
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Small-Cap ETF (Symbol: SCHA) where we have detected an approximate $550.8 million dollar outflow -- that's a 3.3% decrease week over week - 2025-03-17 12:52:32
iShares MSCI World Small Cap UCITS ETF USD (Acc) ITCI holdings
| Date | Number of ITCI Shares Held | Base Market Value of ITCI Shares | Local Market Value of ITCI Shares | Change in ITCI Shares Held | Change in ITCI Base Value | Current Price per ITCI Share Held | Previous Price per ITCI Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ITCI by Blackrock for IE00BF4RFH31
Show aggregate share trades of ITCI| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-03-28 | BUY | 1,330 | | | 131.810* | | 109.91 |
| 2025-03-12 | SELL | -266 | | | 131.250* | | 106.75  Profit of 28,396 on sale |
| 2025-03-04 | SELL | -266 | | | 131.240* | | 105.16 Profit of 27,973 on sale |
| 2025-02-28 | SELL | -1,904 | | | 128.200* | | 104.51 Profit of 198,979 on sale |
| 2025-02-26 | SELL | -552 | | | 128.460* | | 103.85 Profit of 57,326 on sale |
| 2025-02-13 | BUY | 2,157 | | | 128.060* | | 100.42 |
| 2025-02-12 | BUY | 532 | | | 127.970* | | 99.98 |
| 2025-01-27 | BUY | 133 | | | 127.210* | | 93.60 |
| 2025-01-23 | BUY | 133 | | | 127.070* | | 92.23 |
| 2025-01-15 | BUY | 1,911 | | | 126.710* | | 86.50 |
| 2025-01-08 | SELL | -910 | | | 82.560* | | 84.29 Profit of 76,706 on sale |
| 2024-12-18 | BUY | 520 | | | 86.720* | | 84.25 |
| 2024-12-09 | BUY | 4,680 | | | 84.960* | | 84.26 |
| 2024-12-04 | BUY | 260 | | | 85.950* | | 84.20 |
| 2024-12-03 | BUY | 390 | | | 85.310* | | 84.16 |
| 2024-11-19 | BUY | 780 | | | 83.350* | | 83.33 |
| 2024-11-18 | BUY | 260 | | | 82.470* | | 83.38 |
| 2024-11-12 | BUY | 516 | | | 88.490* | | 83.06 |
| 2024-11-11 | BUY | 129 | | | 91.570* | | 82.50 |
| 2024-11-07 | BUY | 645 | | | 90.510* | | 81.20 |
| 2024-10-23 | BUY | 258 | | | 75.020* | | 77.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ITCI
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-04-01 | 773,058 | 399 | 1,138,876 | 67.9% |
| 2025-03-31 | 181,469 | 296 | 556,143 | 32.6% |
| 2025-03-28 | 121,144 | 10,518 | 391,183 | 31.0% |
| 2025-03-27 | 61,816 | 11,255 | 411,769 | 15.0% |
| 2025-03-26 | 44,818 | 201 | 289,317 | 15.5% |
| 2025-03-25 | 73,685 | 100 | 355,588 | 20.7% |
| 2025-03-24 | 41,946 | 5 | 125,567 | 33.4% |
| 2025-03-21 | 136,237 | 0 | 449,384 | 30.3% |
| 2025-03-20 | 223,583 | 750 | 364,723 | 61.3% |
| 2025-03-19 | 29,888 | 49 | 530,908 | 5.6% |
| 2025-03-18 | 19,755 | 240 | 223,607 | 8.8% |
| 2025-03-17 | 53,906 | 0 | 222,814 | 24.2% |
| 2025-03-14 | 93,188 | 1 | 279,860 | 33.3% |
| 2025-03-13 | 71,560 | 27,820 | 532,173 | 13.4% |
| 2025-03-12 | 300,615 | 213,144 | 782,628 | 38.4% |
| 2025-03-11 | 632,677 | 526,837 | 815,398 | 77.6% |
| 2025-03-10 | 249,473 | 15,501 | 919,984 | 27.1% |
| 2025-03-07 | 69,847 | 34 | 310,449 | 22.5% |
| 2025-03-06 | 43,928 | 852 | 315,352 | 13.9% |
| 2025-03-05 | 307,864 | 7 | 1,442,758 | 21.3% |
| 2025-03-04 | 114,301 | 162 | 893,505 | 12.8% |
| 2025-03-03 | 399,372 | 1,407 | 2,726,267 | 14.6% |
| 2025-02-28 | 62,876 | 869 | 413,837 | 15.2% |
| 2025-02-27 | 117,613 | 28,149 | 569,074 | 20.7% |
| 2025-02-26 | 160,341 | 0 | 839,638 | 19.1% |
| 2025-02-25 | 113,859 | 168 | 801,487 | 14.2% |
| 2025-02-24 | 108,728 | 1,403 | 668,727 | 16.3% |
| 2025-02-21 | 75,760 | 200 | 478,195 | 15.8% |
| 2025-02-20 | 54,386 | 0 | 647,918 | 8.4% |
| 2025-02-19 | 166,231 | 938 | 1,106,363 | 15.0% |
| 2025-02-18 | 82,280 | 9,143 | 630,654 | 13.0% |
| 2025-02-14 | 113,974 | 2,172 | 411,699 | 27.7% |
| 2025-02-13 | 75,448 | 5,925 | 451,981 | 16.7% |
| 2025-02-12 | 119,898 | 4,194 | 463,858 | 25.8% |
| 2025-02-11 | 145,521 | 20 | 564,856 | 25.8% |
| 2025-02-10 | 138,633 | 0 | 340,243 | 40.7% |
| 2025-02-07 | 84,190 | 8,470 | 281,913 | 29.9% |
| 2025-02-06 | 156,713 | 8 | 844,590 | 18.6% |
| 2025-02-05 | 231,569 | 30 | 941,638 | 24.6% |
| 2025-02-04 | 163,624 | 47 | 1,769,519 | 9.2% |
| 2025-02-03 | 172,153 | 3,154 | 551,655 | 31.2% |
| 2025-01-31 | 49,100 | 675 | 559,396 | 8.8% |
| 2025-01-30 | 66,539 | 30 | 1,124,807 | 5.9% |
| 2025-01-29 | 171,792 | 4,541 | 1,295,193 | 13.3% |
| 2025-01-28 | 57,091 | 431 | 1,158,767 | 4.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy